Article

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer types

2024-11-18

Abstract excerpt

<h4>ABSTRACT</h4> The KRAS gene is among the most frequently altered genes in cancer and the KRAS protein was long deemed undruggable. Recent strategies to target oncogenic KRAS have included both direct inhibition of the KRAS protein and indirect inhibition of its activity by targeting upstream and downstream signaling pathway mediators. A high-throughput screen of multi-cell type tumor spheroids was designed to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 03b177f8-f451-5acb-9662-4c5fe719a8d7
DOI: 10.1101/2024.11.17.623998

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer typesDOI 10.1101/2024.11.17.623998Read

Targeting KRAS in cancer.Semantic proximity Read

Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele AmplificationSemantic proximity Read

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Semantic proximity Read

Targeting Mutated KRAS Genes to Treat Solid Tumours.Semantic proximity Read

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.Semantic proximity Read

Recent advances in therapeutic targeting of the KRAS pathway in cancer.Semantic proximity Read

Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.Semantic proximity Read

From bench to bedside: current development and emerging trend of KRAS-targeted therapy.Semantic proximity Read

Combinatorial strategies to target RAS-driven cancers.Semantic proximity Read

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Semantic proximity Read

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS-mutant cancers.Semantic proximity Read